The Indian Pharmaceutical market size is expected to become USD 55 Billion by 2020. The major advantage for investors is the fact that 100% FDI is allowed under the automatic route for Greenfield pharma companies. Generic drugs from India account for 20% of global exports and is growing steadily.

Leveraging Assam Ecosystem:

The State has the presence of some key pharmaceutical industries in the country. These industries have capitalised on the incentives, business environment and the availability of crucial bio resources used in medical practices. The state is home to 952 species of medicinal herbs. Proximity of the State to ASEAN Economies provided ready market for export

1. USD 142 Million investments have been made by 9 pharmaceutical units within last 1 year
2. Proximity to ‘Import oriented’ pharmaceutical markets in ASEAN economies
3. Home to more than 10 Biotech and Pharmaceutical institutes
4. Blessed with more than 952 species of plants used in medical practices

Key Infrastructure in Assam:

1. Pharmaceuticals Hub at Balipara, Assam - 35 acres
2. Guwahati Biotech Park
3. Proposed Pharmaceutical Park at Chaygaon, Kamrup -120 acres

Growth Drivers

• High Demand
• Rich Bio Diversity
• Dedicated Biotech Zones
• Slew of Incentives
• Pro Industry Environment
• Strong Intellectual Capital
• Availability of Manpower